Time Ticks For Lantus With Tentative Approval Of Lilly/BI’s Basaglar
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA granted tentative approval for Lilly’s version of insulin glargine, which will compete directly with Sanofi’s Lantus and is expected to be priced lower. Patent issues need to be resolved first, however.